Literature DB >> 17164771

Transduction of brain by herpes simplex virus vectors.

Bradford K Berges1, John H Wolfe, Nigel W Fraser.   

Abstract

An imposing obstacle to gene therapy is the inability to transduce all of the necessary cells in a target organ. This certainly applies to gene transfer to the brain, especially when one considers the challenges involved in scaling up transduction from animal models to use in the clinic. Non-neurotropic viral gene transfer vectors (e.g., adenovirus, adeno-associated virus, and lentivirus) do not spread very far in the nervous system, and consequently these vectors transduce brain regions mostly near the injection site in adult animals. This indicates that numerous, well-spaced injections would be required to achieve widespread transduction in a large brain with these vectors. In contrast, herpes simplex virus type 1 (HSV-1) is a promising vector for widespread gene transfer to the brain owing to the innate ability of the virus to spread through the nervous system and form latent infections in neurons that last for the lifetime of the infected individual. In this review, we summarize the published literature of the transduction patterns produced by attenuated HSV-1 vectors in small animals as a function of the injection site, and discuss the implications of the distribution for widespread gene transfer to the large animal brain.

Entities:  

Mesh:

Year:  2007        PMID: 17164771     DOI: 10.1038/sj.mt.6300018

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  32 in total

Review 1.  Progress in transduction of cerebellar Purkinje cells in vivo using viral vectors.

Authors:  Hirokazu Hirai
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

2.  Telencephalic neurons monosynaptically link brainstem and forebrain premotor networks necessary for song.

Authors:  Todd F Roberts; Marguerita E Klein; M Fabiana Kubke; J Martin Wild; Richard Mooney
Journal:  J Neurosci       Date:  2008-03-26       Impact factor: 6.167

Review 3.  Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

Authors:  Seung T Lim; Mikko Airavaara; Brandon K Harvey
Journal:  Pharmacol Res       Date:  2009-10-17       Impact factor: 7.658

4.  CRF-amplified neuronal TLR4/MCP-1 signaling regulates alcohol self-administration.

Authors:  Harry L June; Juan Liu; Kaitlin T Warnock; Kimberly A Bell; Irina Balan; Dominique Bollino; Adam Puche; Laure Aurelian
Journal:  Neuropsychopharmacology       Date:  2015-01-08       Impact factor: 7.853

Review 5.  Antioxidant enzyme gene transfer for ischemic diseases.

Authors:  Jian Wu; James G Hecker; Nipavan Chiamvimonvat
Journal:  Adv Drug Deliv Rev       Date:  2009-02-20       Impact factor: 15.470

6.  Gene therapy in large animal models of human genetic diseases. Introduction.

Authors:  John H Wolfe
Journal:  ILAR J       Date:  2009

7.  Prospects for the use of artificial chromosomes and minichromosome-like episomes in gene therapy.

Authors:  Sara Pérez-Luz; Javier Díaz-Nido
Journal:  J Biomed Biotechnol       Date:  2010-08-24

8.  An adeno-associated viral vector transduces the rat hypothalamus and amygdala more efficient than a lentiviral vector.

Authors:  Marijke W A de Backer; Carlos P Fitzsimons; Maike A D Brans; Mieneke C M Luijendijk; Keith M Garner; Erno Vreugdenhil; Roger A H Adan
Journal:  BMC Neurosci       Date:  2010-07-13       Impact factor: 3.288

Review 9.  Recent gene therapy advancements for neurological diseases.

Authors:  Sahana Nagabhushan Kalburgi; Nadia N Khan; Steven J Gray
Journal:  Discov Med       Date:  2013-02       Impact factor: 2.970

10.  Short Promoters in Viral Vectors Drive Selective Expression in Mammalian Inhibitory Neurons, but do not Restrict Activity to Specific Inhibitory Cell-Types.

Authors:  Jason L Nathanson; Roberto Jappelli; Eric D Scheeff; Gerard Manning; Kunihiko Obata; Sydney Brenner; Edward M Callaway
Journal:  Front Neural Circuits       Date:  2009-11-09       Impact factor: 3.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.